Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login



NHS England offers to fund doubling of PrEP trial

The expansion of the PrEP trial has been welcomed by both charities and researchers.

PrEP pills and contained


Pre-exposure prophylaxis (PrEP) is a combination of two antiviral drugs which can significantly reduce the risk of HIV transmission

NHS England has said it will fund a doubling of the size of its trial of the HIV prevention drug PrEP to provide an additional 13,000 patients with the drug.

The ‘PrEP Impact Trial’, which currently has over 10,000 participants enrolled with the HIV prevention measure, has been criticised for its cap on the number of places available at sexual health clinics, meaning that people who are not taking part in the trial are having to pay for their own drugs or rely on charities as a result.

According to the National AIDS Trust, some people who have been turned away from clinics after requesting PrEP have gone on to acquire HIV.

A three-year PrEP pilot in Wales began in early 2017, and in Scotland the use of Truvada for PrEP on the NHS was approved by the Scottish Medicines Consortium on 10 April 2017.

In Northern Ireland, PrEP is only available to those who can afford to buy it privately, but in August 2018, the Terrence Higgins Trust announced that it would launch a PrEP access fund in autumn 2018 to support people in both England and Northern Ireland who cannot access or afford the drug.

NHS England said demand for PrEP had “significantly exceeded initial expert predictions”, and that researchers had requested an increase in the number of participants of up to 26,000 by the end of the trial in 2020.

Supporting the researchers’ proposal, NHS England said it would commit to funding additional places in line with existing trial funding arrangements. The trial expansion requires approval from a trial oversight board expected to meet later in January 2019.

John Stewart, director of specialised commissioning at NHS England, said that additional funding would “help ensure the learning from the trial is robust enough to fully inform the planning of a national PrEP programme in partnership with local authorities for the future, as well as protecting more people from HIV right now”.

Deborah Gold, chief executive of the National AIDS Trust, said the NHS England announcement was “a welcome step on the path to PrEP access”.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206000

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.